Short title for running head: KLF1 mutations cause congenital hemolytic anemia
Introduction
Anemia is a major public health problem affecting over 1.5 billion people worldwide. 1 The major causes of anemia include malnutrition, particularly iron and folate deficiency, and infections including malaria and HIV. However, a substantial proportion of patients with anemia have inherited defects of red cells, with mutations found in genes encoding red cell enzymes, membrane proteins, heme and globins. For example, every year over 300,000 affected individuals are born with severe anemia resulting from inherited hemoglobinopathies. 2 However, following screening for mutations in genes currently known to underlie red cell defects, there are many cases of inherited anemia in which either the patient's clinical and hematological phenotype is not consistent with their described genotype, or in whom the cause of the anemia remains completely unknown.
Here we report 8 unrelated patients who displayed severe, transfusion-dependent neonatal anemia with red cell abnormalities ranging from a thalassemia-like morphology (with hypochromic microcytic red cells) to that usually associated with chronic nonspherocytic hemolytic anemias (CNSHA) with anisopoikilocytosis, fragmented cells and a high reticulocyte count. In addition, all of the probands had a remarkable persistence of fetal and embryonic globin synthesis. We found that the parents of these children also had significantly raised levels of fetal hemoglobin (HbF) consistent with previous observations in heterozygotes for KLF1 mutations. In the light of emerging evidence that mutations in KLF1, the gene encoding erythroid Krüppel-like factor (EKLF), give rise to persistent postnatal γ-globin expression in humans [3] [4] [5] [6] [7] and embryonic globin expression in mice 8, 9 we sequenced this gene in the probands. We discovered that all of them are compound heterozygotes for mutations in KLF1. Only three compound heterozygotes for KLF1 mutations have been previously reported and their phenotypes only partially described [6] [7] . The transcription factor KLF1 is a master regulator of terminal erythroid differentiation controlling expression of many key pathways and structures including cell division, the cell membrane and cytoskeleton, iron metabolism, heme-and globinsynthesis 5 . Here, we show that individuals with mutations affecting both alleles of KLF1 exhibit severe anemia in which one or more of these pathways is significantly disrupted
For personal use only. on . by guest www.bloodjournal.org From 4 giving rise to a wide spectrum of hematological phenotypes. The syndromes described here add to an increasing list of trans-acting mutations which cause unusual forms of inherited anemia. [10] [11] [12] [13] Most importantly all such patients show persistent expression of substantial amounts of embryonic hemoglobins in adult life. Despite extensive characterization of the patterns of globin expression in millions of patients in the last 30 years persistent expression of embryonic globins in adults has very rarely been reported.
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Materials and Methods

Blood samples
Blood was collected from all patients and parents after signing a written informed consent.
Patients on regular blood transfusion had a period of at least 10 weeks without blood transfusions before sample collection. This study was approved by the local ethical committees at Siriraj hospital, Bangkok, Thailand and at the John Radcliffe Hospital, Oxford, UK. This study was conducted in accordance with the Declaration of Helsinki.
Hematology and blood serum factors
Routine hematology was determined using an automated red blood cell counter (Sysmex F280, Kobe, Japan). Hemoglobin was analyzed by liquid chromatography using an automated hemoglobin analyzer (HB GOLD; Cumbria, Burrow-in-Furness, UK) and by isoelectric focusing (RESOLVE ® , PerkinElmer, USA). Abnormal hemoglobins were excised from the IEF gel, digested with trypsin and analyzed using matrix-assisted laser desorption/ionization time-of flight (MALDI-TOF/TOF) mass spectrometer (Ultralex Bruker Daltonics, Coventry, UK). Routine biochemical parameters were measured using standard techniques.
Red cell phenotype analysis
Samples were tested for the Lutheran blood group using gel card (DiaMed, Cressier sur reticulocytes contain higher amounts of these enzymes than mature red blood cells, a calculation for the net activities of each enzyme by correction for the reticulocyte number was performed in order to compare with our standard reference range. 15 Flow cytometry to assess the proportions of Hb F, 16 Hb Bart's(γ4), Hb zeta (ζ) and CD44
was performed on mature erythrocytes (CD71-) and circulating erythroblasts (CD71+) of patients and parents. In addition, leukocytes were stained with CD44 and CD45 after lysis of erythrocytes with FACs lysis solution (BD Biosciences, San Jose, CA, USA). The antibodies used were anti-Hb F directly conjugated to FITC (Caltag, Burlingame, CA, USA), anti-Hb Bart's (γ4), anti-Hb zeta (ζ), CD44 PE, CD45 Per CP and CD71 PE-Cy5
(BD Biosciences, San Jose, CA,USA) and isotype controls (mouse immunoglobulin G FITC and FITC-conjugated F(ab')2 anti-mouse globulin (Dako, Cambridge,UK).
Molecular characterization of the globin, KLF1 and PKLR genes
We performed multiplex GAP-PCR 17 and ARMS-PCR for detection of common α -thalassemia mutations. 18 Sequence analysis was performed on 1.3 kb of the α2 and α1, Supplementary Table 6 . A Multiplex Ligation-dependent Probe Amplification (MLPA) assay was performed to exclude large rearrangements of the β globin cluster. 19 The KLF1 and PKLR genes were amplified and sequenced as previously described.
20,21
Primary erythroid cell culture and expression analysis
Erythroid cells were obtained using a two-phase culture system 22 
Results
Clinical Presentation
All eight patients reported here presented with neonatal jaundice requiring phototherapy and, in five cases, blood transfusion. Most patients were anemic at presentation with marked hepato-splenomegaly. By one year of age, all patients had received at least one blood transfusion and subsequently all required regular transfusion during the first years of life. Three patients required splenectomy due to hypersplenism. A summary of the clinical presentations and disease severity of the eight probands is presented in Supplementary Table 1 and associated footnotes.
Hematological Evaluation
Full blood counts were determined for all eight index patients, their parents and available siblings ( Table 1) . Despite transfusion, the levels of Hb in the probands (range 3.0 g/dl to 8.3 g/dl) were low in some cases (Table 1) . With one exception (P-1), all of the patients had hypochromic red cells (MCH 20.1-24.8 pg), suggesting abnormalities in the heme and/or globin synthesis pathways. All of the patients showed raised numbers of reticulocytes (5-16%) and many nucleated red blood cells in the peripheral blood, suggesting a significant hemolytic component to the anemia. The morphology of the peripheral blood was variable. In some patients (P-1, Figure 1A , and P-2-4, Supplementary Figure 1) , the peripheral blood resembled that seen in patients with thalassemia, with marked hypochromasia, microcytosis, anisopoikilocytosis, target cells and fragmented red cells. In those patients who co-inherited globin gene defects the severity of the changes was much greater than normally associated with these genotypes. By contrast, the peripheral blood of others (P5, Figure 1B , and P6-8, Supplementary Figure 1 ) resembled that seen in non-spherocytic hemolytic anemia, with numerous fragmented red blood cells, schistocytes and acanthocytes.
The parents and siblings of the eight affected individuals were not anemic g/dl) although many of them had abnormal red cell indices because they are carriers for 
Analysis of Hemoglobin
Hemoglobin analysis revealed abnormally high levels of HbF (average 38%, range 2.6-54.6%) in all patients, consistent with increased F cells by flow cytometry (heterocellular pattern, Supplementary Table 2 ). Two unanticipated hemoglobins present at levels of up to 18% were observed in all patients. Using, IEF and MALDI-TOF mass spectrometry Table 2 ).
Hb Gower 2 (α 2 ε 2 ) was not detected at significant amounts and other minor bands (which may correspond to Hb Gower 1, ζ 2 ε 2 ) were not examined further. Increased levels of embryonic ζ and ε globin mRNA expression were observed by analysis of cDNA extracted from the peripheral blood of patient P-2 using a tiled microarray (Figure 2A , B) and in other five patients using real-time PCR assays ( Figure 2C ). Interestingly, significantly increased proportions of HbF was observed in 14 of 15 parents from the index families (range 0.2-4.7 %, average (SD); 2.34 + 1.34%, Table 1 ) but none of the parents expressed Hb Bart's or embryonic globins as assessed by chromatography and IEF ( Table 1) . Detection of F-cells, anti-ζ and anti-Bart's using flow cytometry was variable in these parents and siblings (Supplementary Table 2 ).
Analysis of Structural Proteins Commonly Mutated in Red Cell Disorders
Only two of the probands (P-1 and P-5) were found to have entirely structurally normal α-and β-globin genes. The other patients were single or double heterozygotes for common mutations of the globin genes. However, their clinical severity far exceeded that seen in their relatives or other carriers of thalassemia. All patients, and many of the parents, had unexplained, increased levels of HbF, which could have been linked to deletion(s) 25 However, we excluded the possibility of mutations lying within the cis-regulatory regions involved in γ-globin gene expression using multiplexligation probe assays and sequencing analysis (Supplementary Figure 3 and   Supplementary Table 3) .
Although the hematological profiles in these patients were complex, four (P-5 to P-8)
were initially diagnosed with red cell enzymopathies. 26 These patients were tested for eight common red cell enzyme activities and were found to have significant pyruvate kinase deficiency (<50% of normal after reticulocyte count correction). Based on these findings we evaluated the PK status of the remaining four patients (P-1 to P-4) in whom we did not initially suspect any enzymopathy. All had significantly reduced levels of PK activity (Supplementary Table 2 ). However, DNA sequencing of the coding region including the intron/exon boundaries of the PKLR gene, encoding the red cell pyruvate kinase enzyme, failed to identify any causative mutations.
We next evaluated expression of proteins present on the red-cell membrane and in the cytoskeleton. Extensive minor blood group analysis in five index families is summarized in Supplementary Table 4 . All patients had the rare In(Lu) blood group phenotype (a -/b -).
In addition, all parents and siblings, except one (the father of P-2), also expressed this rare blood group phenotype. The In(Lu) phenotype results from the suppression of two cell surface glycoproteins BCAM and CD44 which carry the Lutheran blood group antigens. 21 It has previously been shown that carriers of KLF1 mutations have the In(Lu) phenotype and expression of CD44 was significantly reduced in the erythrocytes of the majority of patients tested (Supplementary Table 2 ) but not in their leukocytes, whereas expression of the cytoskeletal protein Band 3 evaluated by EMA binding assay, appeared unchanged compared to control samples (Supplementary Table 2 ).
Identification of mutations in the KLF1 genes
Although the levels of embryonic (ζ and ε) and fetal (γ) globin RNA and protein are significantly elevated in all probands, analysis of their globin gene haplotypes showed that they have inherited quite different combinations of α and β globin haplotypes (supplementary Figures 6 and 7) . Given that elevations in embryonic globins due to cisacting mutations have never been described previously, it seemed very unlikely that these patients had inherited a variety of cis-mutations causing persistent embryonic gene expression. To analyze this in further detail the embryonic ζ and ε genes, and the fetal γ genes were sequenced in all patients but no changes (other than common single nucleotide polymorphisms) were found. These observations led us to hypothesize that the genetic lesion in these patients may lie in a trans-acting factor involved in erythroid differentiation and maturation. We therefore DNA sequenced the coding region and intron/exon boundaries of two key erythroid transcription factors, GATA1 and KLF1, in one proband (P-2). No likely pathogenic changes were identified in the GATA1 gene, however, we found two changes in KLF1, a c.902G>A transition leading to a p.R301H substitution and a novel 7 bp insertion (c.525_526InsCGGCGCC) resulting in a frameshift (p.G176RfsX179) and disruption of the protein prior to the zinc finger DNA binding domain ( Figure 3 and Table 1 ). Each of these sequence changes has a separate parental origin. The c.902G>A change has been previously reported to underlie elevated levels of HbF as has a similar 7bp insertion (leading to p.G176AfsX179). 6 To gain further genetic evidence that compound heterozygosity for deleterious KLF1 alleles may underlie the abnormalities reported here we DNA sequenced this gene in the seven remaining patients. Surprisingly, we found all seven to be compound heterozygotes for likely pathogenic KLF1 changes ( Figure 3 , Table 1 
KLF1 Target genes
The predominant hematological phenotypes in these compound heterozygotes appear to arise from the effects of KLF1 on the globin genes (causing abnormal globin synthesis) and the genes encoding CD44 (causing the In(Lu) phenotype) and pyruvate kinase (causing CNSHA). Of interest, based on re-analysis of previously published data Table 5 ), these erythroid genes are amongst the most sensitive to changes in the levels of KLF1. Others have previously analyzed the binding of KLF1 to cis-elements surrounding the globin genes and the CD44 gene. 27 Here we have analyzed binding of KLF1 to the PKLR gene (based on data from reference 28 showing that it specifically binds the erythroid promoter of this gene (Figure 4 ). This is clearly consistent with mutations in the KLF1 gene causing severe down-regulation of the levels of PK resulting in CNSHA. It was of interest that all patients with the CNSHA phenotype and PK deficiency (P-5-P-8) have exactly the same combination of mutations (p.G176RfsX179;p.A298P - Table 1 ). Finally, it was of interest that in a single case (P-2)
that could be analyzed, the level of BCL11A mRNA was reduced (Supplementary Figure   5 ) when both alleles of the KLF1 gene are mutated. This is consistent with previous observations showing that this gene is a direct target of KLF1 and is normally involved in the silencing of γ globin synthesis. 3, 4 Following on from observations of the effect of BCL11A deficiency on embryonic globin expression in the mouse 29 , and the anecdotal observation that embryonic expression is increased in a patient with congenital dyserythropoietic anemia type IV associated with a dominantly acting KLF1 mutation (E325K). 30 It seems plausible that when KLF1 is downregulated to a critical level, it also has a similar effect on human embryonic globin expression.
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Discussion
We have defined a new cause of severe anemia in pediatric patients who are compound heterozygotes for mutations in the key erythroid transcription factor KLF1. The cardinal features of this condition are transfusion dependent anemia associated with abnormalities in red cell enzymes (e.g. PK deficiency), red cell membranes (In(Lu) phenotype), and an abnormal pattern of globin synthesis with very high levels of HbF and readily detectable levels of embryonic globins in adult life.
It appears that KLF1 mutations may cause a wide spectrum of phenotypes and this may have been expected from its pleiotropic role in erythropoiesis. The principles emerging from current studies suggest that both the levels of KLF1 and the type of mutated protein produced may exert different effects on KLF1 target genes and consequently cause a wide range of red cell phenotypes. The nonsense mutation G176RfsX179 was identified in five of the families reported here and is similar to the G176AfsX179 reported in two individuals from Korea and Vietnam, 6 but no patients have inherited two nonsense mutations. It seems likely that this would lead to embryonic or early fetal lethality due to severe in utero anemia as occurs in null mice. 31 This warrants further studies of KLF1 in families with unexplained, recurrent hydrops fetalis or fetal loss, which cannot be accounted for by other conditions.
It has previously been shown that a mutation (E325K) in the second zinc finger domain of KLF1 causes a significant alteration in DNA binding especially at the β-globin genes resulting in a severe red cell and clinical phenotype (congenital dyserythropoietic anemia, CDA) even when only one allele is mutated. 29 It is thought that this mutation acts as a dominant negative, gain of function mutation. By contrast, the patients described here have newly defined phenotypes (severe thalassemia or CNSHA) associated with KLF1 mutations. It is of interest that all patients with CNSHA had exactly the same genotype ( 32 Given the widespread effects of KLF1 in erythropoiesis summarized here, it seems unlikely that this study and that of Satta et al 7 have captured the full spectrum of these inherited anemias. Despite the apparent relationship between genotype and phenotype, it is interesting that all three previously described compound heterozygotes for KLF1 mutations (p.S270X/p.K332Q) 7 and (G176Afs179X;L51R) 6 all had similarly raised levels of HbF (22, 31 and 9.5%) but rather milder anemia (Hb 12.1, 11.5 and 13.7 g/dl) than the patients described here. However, two of these were adults (aged over 30 years) 7 when analyzed and also harbored a mutation (p.K322Q) which, in vitro, had only a mildly decreased DNA binding affinity to the promoters tested (∼2 fold) and therefore may represent a relatively mild hypomorphic allele. 33 The age of the third patient is not reported. We have noticed (anecdotally) that the anemia in our patients has improved with age, requiring progressively less transfusion. It will be important to follow up all patients with KLF1 mutations to determine whether severity may be truly age dependent.
Over the past few years the role played by KLF1 in globin gene regulation has become clearer. 5, 34 Almost since its discovery, it has been known that KLF1 is an activator of β globin expression, but more recently it has been shown to play a role in silencing γ globin expression probably by regulating BCL11A and its interaction with Sox6 at the γ globin gene. 3, 35, 36 Mutations in KLF1 therefore reduce β globin expression (causing β thalassemia) 31 and de-repress γ globin expression thereby increasing the synthesis of HbF. 4 However, the relationship between these effects and the mutations that down regulate KLF1 are not straightforward; not all heterozygotes for KLF1 mutations produce increased levels of HbF 37 and, in those who do, the level can be very different even in the presence of the same mutation, demonstrating variable penetrance. 7, 36, 37 These observations have led to speculation about the role of KLF in regulating the levels of HbF. 35 The data presented here clarify the situation since all reported compound heterozygotes produce substantial amounts of HbF putting beyond doubt that KLF1 plays a major role in normally repressing γ globin synthesis in humans in vivo. Reactivation of For personal use only. on October 31, 2017. by guest www.bloodjournal.org From γ globin synthesis by down-regulating KLF1 might provide a way to ameliorate the effect of severe β-hemoglobinopathies. 3, 38 In mice, which do not have a fetal stage of erythropoiesis, the KLF1/BCL11A circuit affects embryonic rather than fetal gene expression. 39 This pathway normally suppresses embryonic globin synthesis in definitive erythroid cells, but a knockout of Klf1 appears to have no effect on embryonic globins in primitive erythropoiesis, when they are normally expressed. In this model definitive cells are not produced to determine whether or not the embryonic genes are correctly suppressed later in development. 5 It was reported anecdotally that a patient with CDA type IV and the E325K mutation had raised levels of embryonic globins. Here we show that in compound KLF1 heterozygotes, human embryonic (ζ and ε) globin expression persists in adults. This indicates that KLF1 also plays a role in repressing embryonic globin expression in humans. This finding is striking since reactivation of embryonic globin is virtually never seen in other erythroid disorders. At present the pathway underlying embryonic globin repression is poorly understood. However it has recently been shown that two members of the KLF family (KLF3 and KLF8) may be involved in regulating embryonic globin expression, and a knockout of these two transcription factors in erythroid cells de-represses embryonic globin synthesis. 40 Since expression of these two factors is driven by KLF1, it is possible that mutations in this protein might reduce KLF3 and KLF8 leading to derepression of embryonic globins. Further analysis of this pathway is warranted since preliminary studies in mice suggest that persistence of embryonic globin expression could ameliorate severe hemoglobinothathies. 41 In conclusion, we have shown that a wide spectrum of unexplained forms of severe inherited anemia may be caused by trans acting mutations in the key erythroid transcription factor KLF1. Most remarkably in every case where the downregulation is sufficiently severe to cause anemia, there is an associated persistence of embryonic globin expression, revealing a new pathway by which globin gene expression might be manipulated to ameliorate other inherited hemoglobinopathies.
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Legends to Table
Family A: * This study was done when this patient was first referred to our hospital and 2 months after the last blood transfusion. **This study was performed 1 year after splenectomy and the patient was free from blood transfusion. Of note, P-1 is the only patient with a normal MCH (28 pg) suggesting that the co-inheritance of thalassemia makes a significant contribution to the defects in Hb synthesis seen in our patients.
Family B: *This study was performed when the patient (P-2) was first seen at our hospital in 1997 (6 month old). # The patient received less than 1 month of blood transfusion before this study and he has been on regular transfusion since. Family C: **The patient was withheld from regular blood transfusion for 4 months before this study. # HbF measurements were variable even within the same individual; at 2 year earlier of this study, Hb F level in the mother and the father were 1.5 and 1.2% respectively by LPLC (same laboratory). Moreover, Hb F levels measured were different based on the techniques used; in the mother Hb F were 4.3%, 3.4% and 3.3% and the father were 0.5%, 0.9% and 0 % based on LPLC, HPLC and capillary electrophoresis (CE) respectively. Using the CE, we were able to discriminate between Hb E and HbA 2 , interestingly, the levels of HbA 2 in the mother was 3.8% (with 20.8% Hb E) and 5.4% (with 26.1% Hb E) in the father. In addition, 0.2% of Hb Constant Spring (Hb CS) eluted at the RT 305 seconds was identified in the mother.
Family D: *This study was done 2 months after blood transfusion when this patient was first referred. **This study was performed 3 months after the regular blood transfusion was held.
Family E: *This study was performed when this patient was withheld from blood transfusion for 10 weeks. ** This study was performed 6 months after splenectomy.
Family F: **This study was performed when this patient was first presented at our hospital.
***This study was performed after the patient was free from blood transfusion for 2 years.
Family G: **This study was performed when this patient first presented at 2 month-old.
Family H: **This evaluation was done when the patient was first referred to our center and the last blood transfusion was around 12 weeks before this study. embryonic globin in the patient remains unclear. There was no significant change on expression of other nearby genes on both clusters. C: Expression profile of erythroid specific genes from primary erythroid cell samples from five patients (P) with KLF1 mutations and normal controls (n= 6) using qPCR and Taqman probe hybridization showing a marked increase of fetal and embryonic globin mRNA expression (HBZ; ζ globin gene, HBE; ε globin gene, HBG; γ globin gene) in all patients with relatively normal expression of KLF1. This suggests that, although, most patients carry one nonsense mutation, that could result in haplo-insufficiency, a missense mutation on the other allele might produce stable transcripts that could be detected at similar levels to normal. Alternatively, our mRNA analysis used might not be sensitive enough to demonstrate a minor perturbation in the level of KLF1 expression. With the exception of BCL11A (B-cell CLL/lymphoma 11A (zinc finger protein) from one patient (P-2), there was no change in expression compared to normal controls of other erythroid specific genes including; CD71, SOX6, ERAF, GYPA; glycophorin A and EPOR; erythropoietin receptor (Supplementary Figure 5) . 
